Biomedico SRL
3.0 FTEBiomedico reported total assets of 689,475 € at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Feb 2026), with 3 full-time equivalents.
The score of Biomedico shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +50 % Total assets +158 % Headcount (avg FTE) +15 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Biomedico's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Feb 2026
- Year ended 31 Dec 2024filed on 18 Jun 2025
- Year ended 31 Dec 2023filed on 24 Jun 2024
Biomedico's financial analysis
- Solvency25.9%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Biomedico
Biomedico's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0793.472.767
- VAT number
- BE0793472767
- Peppol
- Registered · 0208:0793472767 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 10 Nov 2022
- Registered office
- 3110 Rotselaar
- Size
- Micro · 3.0 FTE
- Latest accounts
- 2025 · filed on 26 Feb 2026
- Activity
- Manufacture of other pharmaceutical products (NACE 21209)
Biomedico (SRL) has been based in Rotselaar since 2022, active in: manufacture of other pharmaceutical products. For 2025, it reports a net profit of 35,408 € and equity of 178,528 €; its revenue is not published. With 3.0 full-time equivalents, it is a micro-enterprise by headcount.
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Biomedico
Companies in the same business, of comparable size and area, outside its group.
- Dohmeyer Scientific Applications Wholesale of pharmaceutical and medical goods Roeselare · balance sheet 400,857 €
- Jotherm Wholesale of wood, construction materials and sanitary equipment Aubange · balance sheet 672,954 €
- Clima Construct Wholesale of other machinery and equipment Wommelgem · balance sheet 686,530 €
- Precicom Refrigeration Manufacture of non-domestic air conditioning equipment Mons · balance sheet 664,556 €
- BRU-Pack Non-specialised wholesale trade Saint-Josse-ten-Noode · balance sheet 404,455 €
- Sterisys Wholesale of pharmaceutical and medical goods Raeren · balance sheet €6.28m
- De Ceunynck Radiotherapy Manufacture of pharmaceutical preparations Aartselaar · balance sheet 477,215 €
- DB Services HVAC Manufacture of non-domestic air conditioning equipment Awans · balance sheet €1.06m
Frequently asked questions about Biomedico
What is the revenue of Biomedico?
Biomedico files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Biomedico?
In Belgium, the VAT number is the company number prefixed with BE: BE0793472767 for Biomedico, if the company is VAT-registered. Its company number (CBE) is 0793.472.767.
Where is the registered office of Biomedico?
According to the CBE register, the registered office of Biomedico is in 3110 Rotselaar.
What is the equity of Biomedico?
At the close of the 2025 financial year, the equity of Biomedico amounts to 178,528 €, a solvency of 25.9% of total assets.
How many people work at Biomedico?
3.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Biomedico?
The register lists 2 active mandates at Biomedico. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Biomedico
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →